• Hakkımızda
  • İletişim/Künye
  • Dergimize Abone Olun
  • E-Dergi
MEDİKAL TEKNİK
  • Anasayfa
  • Güncel
  • Medikal Ekipman
  • Sağlık
  • İlaç
  • Röportaj
  • Atama
  • Makale
  • |ENGLISH|
  • E-Dergi
No Result
View All Result
  • Anasayfa
  • Güncel
  • Medikal Ekipman
  • Sağlık
  • İlaç
  • Röportaj
  • Atama
  • Makale
  • |ENGLISH|
  • E-Dergi
No Result
View All Result
MEDİKAL TEKNİK
No Result
View All Result

SmartCella granted new European patent for the Extroducer delivery platform

SmartCella Holding AB (“SmartCella”) today announces that the European Patent Office (EPO) has granted a new European patent for the Extroducer® endovascular delivery platform.

15 Kasım 2024
0
SmartCella granted new European patent for the Extroducer delivery platform

SmartCella is a global innovative biotechnology company that combines novel delivery platforms, such as the Extroducer, with cutting-edge cell and mRNA therapies. The Extroducer is a first-in-class endovascular delivery device that enables direct-to-tissue drug delivery. It addresses a significant unmet clinical need for a wide range of indications, enabling targeted delivery of various modalities to solid tumors and hard-to-reach tissues, including the heart. The Extroducer provides access to these areas by safely penetrating the vessel wall and delivering payload directly to the target location. It can be used in combination with standard imaging equipment and routine interventional radiology approaches.

 

The patent granted by the EPO is the next generation of patents related to the Extroducer delivery platform. This specific patent covers the design of the distal part of the Extroducer, which penetrates the vessel wall and moves smoothly towards the target location. The patent provides protection in 39 relevant countries and is going to remain valid for 20 years, per global patent standards.

 

Niklas Prager, CEO, comments: “We are pleased to have been granted an additional patent for the Extroducer, further strengthening our intellectual property portfolio and solidifying our market position. As the Extroducer is a unique and highly innovative delivery platform, it requires a strong, enduring patent foundation. This is a key element of our go-to-market strategy, enabling our partners to gain a competitive advantage with a minimally invasive route of administration for their therapeutic portfolios. It is essential to protect the Extroducer platform and ensure that the work within our partnerships cannot be duplicated throughout the process, from clinical trials to full commercialization.”

Tags: CEOclinical trialsExtroducerExtroducer platformNiklas PragerpositionSmartCella
Previous Post

Diyabet, Genç Yaşta Katarakt ve Görme Kaybına Neden Olabilir

Next Post

MEDICA 2024 and COMPAMED 2024: medical technology industry uses global reach to compete for innovation leadership

editor

Next Post
MEDICA 2024 and COMPAMED 2024: medical technology industry uses global reach to compete for innovation leadership

MEDICA 2024 and COMPAMED 2024: medical technology industry uses global reach to compete for innovation leadership

Bir yanıt yazın Yanıtı iptal et

E-posta adresiniz yayınlanmayacak. Gerekli alanlar * ile işaretlenmişlerdir

  • Anasayfa
  • Güncel
  • Medikal Ekipman
  • Sağlık
  • İlaç
  • Röportaj
  • Atama
  • Makale
  • |ENGLISH|
  • E-Dergi

© 2024 Medikal Teknik Dergisi.

No Result
View All Result
  • Anasayfa
  • Güncel
  • Medikal Ekipman
  • Sağlık
  • İlaç
  • Röportaj
  • Atama
  • Makale
  • |ENGLISH|
  • E-Dergi

© 2024 Medikal Teknik Dergisi.